NEW HAVEN, Conn., May 1 /PRNewswire/ -- RHEI Pharmaceuticals, Inc., a privately held specialty pharmaceutical company that acquires, licenses, develops and commercializes therapies for market in China, has announced that Scott Kozak has joined the company as Vice President of Commercial Operations. Mr. Kozak joins the company’s executive management team and will report to Chief Executive Officer Dr. Sylvia He. Mr. Kozak will manage the in-licensing, business and corporate development activities of the company.
“Scott’s broad experience at EpiCept, Forest, Hoffman LaRoche and Solvay combine a successful background in business development with a keen understanding of the international pharmaceuticals business,” stated Harry Penner, RHEI Pharmaceutical’s Chairman of the Board. “We look forward to Scott’s success in broadening RHEI’s pipeline of products for the China market.”
Before joining RHEI, Mr. Kozak, 40, served as Vice President of Business Development for EpiCept Corporation, a specialty pharmaceutical company focused on the pain market. While at EpiCept, Mr. Kozak was responsible for all aspects of the business development area including sourcing and managing all licensing and partnering transactions, compiling corporate marketing and business development materials and was responsible for the management of the company’s intellectual property portfolio. While at EpiCept, Mr. Kozak was part of the team that negotiated and finalized the acquisition of Maxim Pharmaceuticals, which provided EpiCept with a Nasdaq listing of the company. Prior to EpiCept, Mr. Kozak was Director of Licensing and Corporate
Development for Forest Laboratories where he was responsible for in-licensing activities, as well as strategic corporate development through out-licensing, alliances and co-promotion. Between 1997 and 2000, Mr. Kozak was a Director of Global Licensing and Corporate Development for Hoffmann La-Roche. He began his pharmaceutical career at Solvay Pharmaceuticals and held positions of increasing responsibility in sales, marketing and business development before leaving in 1997.
“We are fortunate to have recruited an executive with Scott’s wide range of corporate and commercial experience,” said Sylvia He, Ph.D, Chief Executive Officer and co-founder of RHEI Pharmaceuticals. “We are confident that Scott’s contacts and experience will help RHEI achieve its goals.”
About RHEI Pharmaceuticals
RHEI Pharmaceuticals is a venture backed specialty pharmaceutical company with operations in the US and in China that acquires, licenses, develops and commercializes in China proprietary drug therapies based upon the unmet needs of the emerging China pharmaceuticals market. RHEI leverages its proprietary and extensive network of experienced clinical development and regulatory professionals in China to obtain accelerated approvals and market entry for the China market. RHEI’s growing sales and marketing capabilities then maximize patient access in China to new and critically necessary therapeutics. RHEI specializes in hospital-based proprietary products with a therapeutic focus on urgent unmet needs in the areas of cancer, cardiovascular disease, pulmonary disease, pain, anti-infective, and other life threatening conditions.
RHEI Pharmaceuticals, Inc.
CONTACT: Dr. Sylvia He, Chief Executive Officer, or Scott B. Kozak, VicePresident, Commercial Operations, both of RHEI Pharmaceuticals, Inc.,+1-203-624-RHEI (7434); or Tony Ho Loke, media, +1-917-322-2164, or RhondaChiger, investors, +1-917-322-2569, both of Rx Communications Group, forRHEI Pharmaceuticals, Inc.
Web site: http://www.rheipharma.com/
